CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Mediexplorer.it
Reumabase.it

Search results for "Inspra"

The aldosterone antagonist Eplerenone ( Inspra ) has significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis ...


Eplerenone ( Inspra ) is the second MRA to be marketed in Canada after Spironolactone. Eplerenone has a Health Canada indication as an adjunct to standard therapy to reduce the risk of cardiovascular ...


Myocardial infarction patients without heart failure derive no benefit from the addition of mineralocorticoid receptor antagonists ( MRA; antimineralocorticoids ), to standard therapy, results of the ...